home
investors
newsroom
licensing
careers
contact us
About Us
Our Values
Leadership
How We Operate
Views and Positions
Merck/Schering-Plough Merger
Our History
Corporate Responsibility
Ethics and Transparency
Access
Environment
Community
Research
Pipeline
Discovery & Development
Products
Vaccines
Prescription Products
Consumer Products
Animal Health
Prescribing Information
INVESTED IN
YOUR FUTURE
Financials
Annual Reports, Proxy Statements, and Form 10-K
SEC Filings & Certifications
Earnings Releases
Quarterly Financials
Stock Information
Stock Chart
Historical Price Lookup
Stock Splits
Cash Dividend History
Investment Calculator
Partnerships
Events & Presentations
Stockholder Services
Information Request
Contact Us
LATEST NEWS
Nov. 20, 2009
Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA®
Nov. 17, 2009
Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
Nov. 17, 2009
Higher Dose of Merck's COZAAR® (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
More news
Print
Share
Text Size
Product Pipeline
Learn more
Related Information
2008 Merck Annual Report
2008 Schering-Plough Annual Report
Corporate Responsibility Report
Podcast
